If you have been reading about visceral adiposity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
The influence of Nasser's Arab nationalism over the RCC was immediately apparent. The administration was instantly recognized by the neighbouring Arab nationalist regimes in Egypt, Syria, Iraq, and Sudan, with Egypt sending experts to aid the inexperienced RCC. Gaddafi propounded pan-Arab ideas, proclaiming the need for a single Arab state stretching across North Africa and the Middle East. In December 1969, Libya signed the Tripoli Charter alongside Egypt and Sudan. This established the Arab Revolutionary Front, a pan-national union designed as a first step towards the eventual political unification of the three nations. In 1970 Syria declared its intention to join. Nasser died unexpectedly in September 1970, with Gaddafi playing a prominent role at his funeral. Nasser was succeeded by Anwar Sadat, who replaced the idea of a unified state with a political federation, implemented in April 1971; in doing so, Egypt, Syria, and Sudan received large grants of Libyan oil money. In July 1971, Gaddafi sided with Sadat against the Soviet Union in the 1971 Sudanese coup d'état and dispatched Libyan fighter jets to force down a British Overseas Airways Corporation jetliner carrying the leading coup plotters, Farouk Osman Hamadallah and Babikir al-Nour. They were extradited back to Khartoum, where they were promptly executed by Sudanese leader Jaafar Nimeiry. In February 1972, Gaddafi and Sadat signed an unofficial charter of merger, but it was never implemented because relations broke down the next year.
=== Br === Roscoe Brady (1923–2016). American biochemist at the National Institute of Neurological Disorders and Stroke, who identified many enzyme defects responsible for metabolic diseases. Member Natl. Acad. Sci. USA. Herman Branson (1914–1995). American physicist and biochemist who participated at Caltech in the discovery of the α-helix Sydney Brenner (1927–2019). South African biochemist at Cambridge, and later Berkeley, known for work on the genetic code and more recently for establishing Caenorhabditis elegans as a model organism. Nobel prize in Physiology or Medicine (2002) Roger Brent (b. 1955). American molecular biologist at the University of Washington known for work on gene regulation and systems biology Kenneth Breslauer (b. 1947). American biochemist at Rutgers University (born in Sweden of German parents), who has studied DNA damage and repair, including why certain mutations escape repair and result in cancer. Bernard Brodie (1907–1989). American biochemist and pharmacologist at the National Heart Institute, regarded as the founder of modern pharmacology. He studied drug metabolism and the mechanisms of drug effects. Member Natl. Acad. Sci. USA. Adrian John Brown FRS (1852–1920). British expert on brewing and malting at the University of Birmingham. He was a pioneer of enzyme kinetics and proposed an explanation of enzyme saturation. Patrick O. Brown (b. 1954). American biochemist at Stanford.
A football pitch, or field, can be used as a man-in-the-street unit of area. The standard FIFA football pitch for international matches is 105 m (344 ft) long by 68 m (223 ft) wide (7,140 m2 or 0.714 ha or 1.76 acres); FIFA allows for a variance of up to 5 m (16.4 ft) in length in either direction and 7 m (23.0 ft) more or 4 m (13.1 ft) less in width (and larger departures if the pitch is not used for international competition), which generally results in the association football pitch generally only being used for order of magnitude comparisons. An American football field, including both end zones, is 360 by 160 ft (120.0 by 53.3 yd; 109.7 by 48.8 m), or 57,600 square feet (5,350 m2) (0.535 hectares or 1.32 acres). A Canadian football field is 65 yards (59 m) wide and 110 yards (100 m) long with end zones adding a combined 40 yards (37 m) to the length, making it 87,750 square feet (8,152 m2) or 0.8215 ha (2.030 acres). An Australian rules football field may be approximately 150 metres (160 yd) (or more) long goal to goal and 135 metres (148 yd) (or more) wide, although the field's elliptical nature reduces its area to a certain extent. A 150-by-135-metre (164 by 148 yd) football field has an area of approximately 15,900 m2 (1.59 ha; 3.9 acres), twice the area of a Canadian football field and three times that of an American football field.
Despite DuPont's assertion that "cookware coated with DuPont Teflon non-stick coatings does not contain PFOA", residual PFOA was also detected in finished PTFE products including PTFE cookware (4–75 parts per billion). However, PFOA levels ranged from undetectable (<1.5) to 4.3 parts per billion in a more recent study. Also, non-stick cookware is heated—which should volatilize PFOA; PTFE products that are not heated, such as PTFE sealant tape, had higher (1800 parts per billion) levels detected. Overall, PTFE cookware is considered an insignificant exposure pathway to PFOA.
== Clinical significance == AST is similar to alanine transaminase (ALT) in that both enzymes are associated with liver parenchymal cells. The difference is that ALT is found predominantly in the liver, with clinically negligible quantities found in the kidneys, heart, and skeletal muscle, while AST is found in the liver, heart (cardiac muscle), skeletal muscle, kidneys, brain, and red blood cells. As a result, ALT is a more specific indicator of liver inflammation than AST, as AST may be elevated also in diseases affecting other organs, such as myocardial infarction, acute pancreatitis, acute hemolytic anemia, severe burns, acute renal disease, musculoskeletal diseases, and trauma. The elevated AST level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate. AST was defined as a biochemical marker for the diagnosis of acute myocardial infarction in 1954. However, the use of AST for such a diagnosis is now redundant and has been superseded by the cardiac troponins. Laboratory tests should always be interpreted using the reference range from the laboratory that performed the test. Example reference ranges are shown below:
Sources: en.wikipedia.org
== CFNA (alternative to Mosher's acid) == A newer chiral derivatizing agent (CDA), α-cyano-α-fluoro (2-naphthyl)-acetic acid (2-CFNA) was prepared in optically pure form by the chiral HPLC separation of a racemic 2-CFNA methyl ester. This ester was obtained by fluorination of methyl α-cyano (2-naphthyl) acetate with FClO3. 2-CFNA has been shown to be a superior CDA than Mosher's agent to determine the enantiomeric excess of a primary alcohol.
=== Vitamin B12 === Spirulina contains no vitamin B12 naturally, and spirulina supplements are not considered a reliable source of vitamin B12, as they contain predominantly pseudovitamin B12 (Coα-[α-(7-adenyl)]-Coβ-cyanocobamide), which is biologically inactive in humans. In a 2009 position paper on vegetarian diets, the American Dietetic Association stated that spirulina is not a reliable source of active vitamin B12. The medical literature similarly advises that spirulina is unsuitable as a source of B12.
The purest metal is obtained from nickel oxide by the Mond process, which gives a purity of over 99.99%. The process was patented by Ludwig Mond and has been in industrial use since before the beginning of the 20th century. In this process, nickel is treated with carbon monoxide in the presence of a sulfur catalyst at around 40–80 °C to form nickel carbonyl. In a similar reaction with iron, iron pentacarbonyl can form, though this reaction is slow. If necessary, the nickel may be separated by distillation. Dicobalt octacarbonyl is also formed in nickel distillation as a by-product, but it decomposes to tetracobalt dodecacarbonyl at the reaction temperature to give a non-volatile solid. Nickel is obtained from nickel carbonyl by one of two processes. It may be passed through a large chamber at high temperatures in which tens of thousands of nickel spheres (pellets) are constantly stirred. The carbonyl decomposes and deposits pure nickel onto the spheres. In the alternate process, nickel carbonyl is decomposed in a smaller chamber at 230 °C to create a fine nickel powder. The byproduct carbon monoxide is recirculated and reused. The highly pure nickel product is known as "carbonyl nickel".
Joy was considered as a necessary evil for the player; by having their character take the drug, the player would enjoy short-term gains such as getting out of trouble and being able to explore without fear of attacks, but would have negative long-term effects once Joy wore out. Provost considered that with the permadeath mechanic, the player would need to put a great deal of consideration into using Joy as to preserve their current game knowing there will be consequences later.
== Occurrence in food == HMF is practically absent in fresh food, but it is naturally generated in sugar-containing food during heat-treatments like drying or cooking. Along with many other flavor- and color-related substances, HMF is formed in the Maillard reaction as well as during caramelization. In these foods it is also slowly generated during storage. Acid conditions favour generation of HMF. HMF is a well known component of baked goods. Upon toasting bread, the amount increases from 14.8 (5 min.) to 2024.8 mg/kg (60 min). It is also formed during coffee roasting, with up to 769 mg/kg. It is a good wine storage time−temperature marker, especially in sweet wines such as Madeira and those sweetened with grape concentrate arrope.
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.